peyt

Stem Cell Therapy

Consistent cell count & viability for development & manufacturing

Stem cell therapy is one of the most promising medical therapeutic areas of the 21st century. Bone marrow transplanted hematopoietic stem cells (HSCs) used to rebuild bone marrow have been used for a long time. More recently, other types of stem cell therapies are entering clinics. These treatments include using epithelial stem cells for skin graft and retinal replacement treatments1, therapies against Type I diabetes2,3, and neural replacement therapies to target the cause of Alzheimer’s disease4.

In stem cell therapy research and production, it is crucial to determine precise cell concentration and viability for reproducibility of protocols, culture conditions and standardization of the product.

Obtaining reproducible results can be challenging when cells are grown as aggregates, in spheroids or organoids, and when multiple operators are generating data, sometimes at different sites.

In stem cell therapy manufacturing primary stem cells are harvested, cultured, formulated, and administered to the patient.

Solutions for stem cell therapy

Applications of cell-based therapies include the treatment of neurological dysfunctions, gene & drug delivery, ocular repair, and cardiac tissue repair.

To ensure consistency and reproducibility in culturing stem cells, you need to have precise methods for the estimation of cell concentration and viability. NucleoCounter® instruments offer a wide range of specialized assays matching the needs of dedicated stem cell therapeutic laboratories and production facilities.

Our technology features optimized protocols for counting and viability of aggregated and primary cells, including:

 

Documents

TitleCategoriesLink

References

  1. G Pellegrini, D Ardigò, G Milazzo et al.: Navigating Market Authorization: The Path Holoclar Took to Become the First Stem Cell Product Approved in the European Union. Stem Cells Transl Med. 2018;7(1):146-154.
  2. RR Henry, J Pettus, J Wilensky et al.: Initial Clinical Evaluation of VC-01TM Combination Product—A Stem Cell–Derived Islet Replacement for Type 1 Diabetes (T1D). Diabetes 2018 Jul; 67(Supplement 1): -. https://doi.org/10.2337/db18-138-OR
  3. AD Agulnick, DM Ambruzs, MA Moorman et al.: Insulin-Producing Endocrine Cells Differentiated In Vitro From Human Embryonic Stem Cells Function in Macroencapsulation Devices In Vivo. Stem Cells Transl Med. 2015;4(10):1214-22.
  4. X-Y Liu, L-P Yang, L Zhao: Stem cell therapy for Alzheimer’s disease. World J Stem Cells. 2020;12(8):787-802.